Monte Rosa Therapeutics Stock Performance
| GLUE Stock | USD 8.35 0.01 0.12% |
On a scale of 0 to 100, Monte Rosa holds a performance score of 6. The company secures a Beta (Market Risk) of 3.72, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Monte Rosa will likely underperform. Please check Monte Rosa's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Monte Rosa's current price movements will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Monte Rosa exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.41 | Five Day Return 0.88 | Year To Date Return 51.4 | Ten Year Return (59.18) | All Time Return (59.18) |
1 | Disposition of 541897 shares by Versant Venture Capital Vi, L.p. of Monte Rosa at 6.0 subject to Rule 16b-3 | 09/11/2024 |
2 | Disposition of 16047 shares by Versant Venture Capital Vi, L.p. of Monte Rosa at 6.0017 subject to Rule 16b-3 | 09/12/2024 |
3 | Acquisition by Janku Filip of 30000 shares of Monte Rosa at 7.56 subject to Rule 16b-3 | 09/13/2024 |
4 | Acquisition by Skvarka Jan of 41000 shares of Monte Rosa at 7.36 subject to Rule 16b-3 | 09/17/2024 |
5 | Disposition of 1132566 shares by Versant Venture Capital Vi, L.p. of Monte Rosa at 6.5296 subject to Rule 16b-3 | 09/20/2024 |
6 | Versant Venture sells 7.4m in Monte Rosa Therapeutics stock | 09/24/2024 |
7 | Acquisition by Walker Paul Edward of 2715968 shares of Monte Rosa subject to Rule 16b-3 | 09/27/2024 |
8 | Acquisition by Janku Filip of 121000 shares of Monte Rosa at 5.71 subject to Rule 16b-3 | 09/30/2024 |
9 | Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for t... | 10/23/2024 |
10 | Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders | 10/28/2024 |
11 | Monte Rosa Therapeutics, Inc. Major Shareholder Versant Venture Capital Vi, L. Sells 89,990 Shares | 10/30/2024 |
12 | Monte Rosa Therapeutics GAAP EPS of -0.29 | 11/07/2024 |
13 | FY2028 Earnings Forecast for GLUE Issued By Wedbush | 11/12/2024 |
14 | Monte Rosa Therapeutics Trading 9 percent Higher Time to Buy | 11/19/2024 |
| Begin Period Cash Flow | 60.2 M |
Monte |
Monte Rosa Relative Risk vs. Return Landscape
If you would invest 633.00 in Monte Rosa Therapeutics on August 23, 2024 and sell it today you would earn a total of 202.00 from holding Monte Rosa Therapeutics or generate 31.91% return on investment over 90 days. Monte Rosa Therapeutics is currently generating 0.9688% in daily expected returns and assumes 12.6448% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Monte, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Monte Rosa Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Monte Rosa's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Monte Rosa Therapeutics, and traders can use it to determine the average amount a Monte Rosa's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0766
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GLUE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.64 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.97 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Monte Rosa is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Monte Rosa by adding it to a well-diversified portfolio.
Monte Rosa Fundamentals Growth
Monte Stock prices reflect investors' perceptions of the future prospects and financial health of Monte Rosa, and Monte Rosa fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Monte Stock performance.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (2.88) % | ||||
| Current Valuation | 315.12 M | ||||
| Shares Outstanding | 61.44 M | ||||
| Price To Earning | 1.91 X | ||||
| Price To Book | 2.50 X | ||||
| Price To Sales | 34.30 X | ||||
| EBITDA | (137.09 M) | ||||
| Net Income | (135.35 M) | ||||
| Cash And Equivalents | 294.14 M | ||||
| Cash Per Share | 6.32 X | ||||
| Total Debt | 46.04 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 20.11 X | ||||
| Book Value Per Share | 3.35 X | ||||
| Cash Flow From Operations | (43.8 M) | ||||
| Earnings Per Share | (1.78) X | ||||
| Market Capitalization | 513.61 M | ||||
| Total Asset | 303.75 M | ||||
| Retained Earnings | (365.89 M) | ||||
| Working Capital | 189.62 M | ||||
About Monte Rosa Performance
By analyzing Monte Rosa's fundamental ratios, stakeholders can gain valuable insights into Monte Rosa's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Monte Rosa has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Monte Rosa has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 36.85 | 32.75 | |
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.76) | (0.72) |
Things to note about Monte Rosa Therapeutics performance evaluation
Checking the ongoing alerts about Monte Rosa for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Monte Rosa Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Monte Rosa is way too risky over 90 days horizon | |
| Monte Rosa appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (135.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Monte Rosa Therapeutics currently holds about 294.14 M in cash with (43.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.32. | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Monte Rosa Therapeutics Trading 9 percent Higher Time to Buy |
- Analyzing Monte Rosa's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Monte Rosa's stock is overvalued or undervalued compared to its peers.
- Examining Monte Rosa's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Monte Rosa's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Monte Rosa's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Monte Rosa's stock. These opinions can provide insight into Monte Rosa's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |